Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.32 |
| ▸ | FEN1 | P39748 | 6/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31314212 | 0.71 | TDO2 (0.35) | NOS2ALOX5APFEN1 | |
| SCHEMBL2015639 | 0.70 | ALDH1A1 (0.38) | — | |
| SCHEMBL2647857 | 0.70 | TDP1 (0.40) | PSMB5 | |
| SCHEMBL30833923 | 0.70 | TDP1 (0.40) | PSMB5 | |
| SCHEMBL31524176 | 0.70 | TDP1 (0.40) | PSMB5 | |
| SCHEMBL24574595 | 0.70 | PDE10A (0.38) | — | |
| SCHEMBL8111724 | 0.69 | TDP1 (0.36) | — | |
| SCHEMBL12169704 | 0.68 | KMT2A (0.35) | IKBKBNOS2 | |
| SCHEMBL1202243 | 0.67 | TDO2 (0.39) | GRM2FEN1 | |
| SCHEMBL17594697 | 0.67 | RAF1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | disclosed |
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
| EP-1745039-A4 | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES | NEUROGEN CORP (US) | 2009-07-22 | — | — | EP | disclosed |
| CN-1984904-A | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| EP-1745039-A2 | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES | Neurogen Corporation (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006004589-A2 | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES | NEUROGEN CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | MMP25, MMP9, MMP3 | IKBKB 1366/4885HTR2C 1613/4885NOS2 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.